64
Participants
Start Date
March 29, 2018
Primary Completion Date
April 1, 2023
Study Completion Date
May 4, 2023
VRx-3996 and valganciclovir
second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical College - New York Presbyterian Hospital, New York
Thomas Jefferson University, Philadelphia
Fox Chase Cancer Center, Philadelphia
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Winship Cancer Institute, Emory University, Atlanta
Georgia Cancer Center at Augusta University, Augusta
Mid Florida Hematology and Oncology Center, Orange City
ASCLEPES Research Centers, Weeki Wachee
The Ohio State University Wexner Medical Center James Cancer Hospital, Columbus
Indiana Blood and Marrow Transplantation, Indianapolis
Henry Ford Hospital, Detroit
St. Vincent Healthcare Cancer Center, Billings
Northwestern University Feinberg School of Medicine, Chicago
Ruth M Rothstein CORE Center, Chicago
The University of Kansas Cancer Center and Medical Pavilion, Westwood
Texas Oncology - Baylor Sammons Cancer Center, Dallas
University of Colorado Anschutz Cancer Pavilion, Aurora
USC Norris Comprehensive Cancer Center, Los Angeles
University of California, Los Angeles, Los Angeles
UC Irvine Chao Family Comprehensive Cancer Center, Orange
John Theurer Cancer Center at Hackensack UMC, Hackensack
Centro de Hematologia e Oncologia da Bahia (CEHON), Salvador
Hospital de Cancer de Pernambuco (HCP), Recife
Hospital do Cancer Mae de Deus, Porto Alegre
Real e Benemerita Associacao Portuguesa de Beneficencia, São Paulo
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP), São Paulo
Hospital Santa Marcelina, São Paulo
Viracta Therapeutics, Inc.
INDUSTRY